280 related articles for article (PubMed ID: 8154311)
21. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis].
Agnusdei D; Gonnelli S; Camporeale A; Batignani T; Nardi P; Ianes A; Gennari C
Minerva Endocrinol; 1989; 14(3):169-76. PubMed ID: 2695815
[TBL] [Abstract][Full Text] [Related]
22. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study.
Luengo M; Pons F; Martinez de Osaba MJ; Picado C
Thorax; 1994 Nov; 49(11):1099-102. PubMed ID: 7831624
[TBL] [Abstract][Full Text] [Related]
23. Intranasal salmon calcitonin in postmenopausal osteoporosis: effect of different therapeutic regimens on vertebral and peripheral bone density.
Perrone G; Galoppi P; Valente M; Capri O; D'Ubaldo C; Anelli G; Zichella L
Gynecol Obstet Invest; 1992; 33(3):168-71. PubMed ID: 1612530
[TBL] [Abstract][Full Text] [Related]
24. [Comparison of the effectiveness of 17-beta-estradiol and calcitonin in women with postmenopausal bone loss].
Stĕpán J; Formánková J; Masatová A; Michalský M; Rosenová Z
Cas Lek Cesk; 1997 Apr; 136(8):242-8. PubMed ID: 9264868
[TBL] [Abstract][Full Text] [Related]
25. Comparison of calcitriol treatment with etidronate-calcitriol and calcitonin-calcitriol combinations in Turkish women with postmenopausal osteoporosis: a prospective study.
Gürlek A; Bayraktar M; Gedik O
Calcif Tissue Int; 1997 Jul; 61(1):39-43. PubMed ID: 9192511
[TBL] [Abstract][Full Text] [Related]
26. Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers.
Nielsen NM; von der Recke P; Hansen MA; Overgaard K; Christiansen C
Calcif Tissue Int; 1994 Jul; 55(1):8-11. PubMed ID: 7922794
[TBL] [Abstract][Full Text] [Related]
27. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.
Overgaard K; Hansen MA; Jensen SB; Christiansen C
BMJ; 1992 Sep; 305(6853):556-61. PubMed ID: 1393035
[TBL] [Abstract][Full Text] [Related]
28. Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment.
Overgaard K; Hansen MA; Nielsen VA; Riis BJ; Christiansen C
Am J Med; 1990 Jul; 89(1):1-6. PubMed ID: 2152594
[TBL] [Abstract][Full Text] [Related]
29. Treatment of postmenopausal osteoporosis with salmon calcitonin nasal spray: evaluation by bone mineral content and biochemical patterns.
Tolino A; Romano L; Ronsini S; Riccio S; Montemagno U
Int J Clin Pharmacol Ther Toxicol; 1993 Jul; 31(7):358-60. PubMed ID: 8370634
[TBL] [Abstract][Full Text] [Related]
30. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis.
Thamsborg G; Jensen JE; Kollerup G; Hauge EM; Melsen F; Sorensen OH
Bone; 1996 Feb; 18(2):207-12. PubMed ID: 8833216
[TBL] [Abstract][Full Text] [Related]
31. Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study.
Overgaard K; Lindsay R; Christiansen C
Clin Ther; 1995; 17(4):680-5. PubMed ID: 8565031
[TBL] [Abstract][Full Text] [Related]
32. 1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin.
Reginster JY; Denis D; Albert A; Deroisy R; Lecart MP; Fontaine MA; Lambelin P; Franchimont P
Lancet; 1987 Dec; 2(8574):1481-3. PubMed ID: 2892047
[TBL] [Abstract][Full Text] [Related]
33. Calcitonin.
Silverman SL
Am J Med Sci; 1997 Jan; 313(1):13-6. PubMed ID: 9001161
[TBL] [Abstract][Full Text] [Related]
34. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.
Ellerington MC; Hillard TC; Whitcroft SI; Marsh MS; Lees B; Banks LM; Whitehead MI; Stevenson JC
Calcif Tissue Int; 1996 Jul; 59(1):6-11. PubMed ID: 8661976
[TBL] [Abstract][Full Text] [Related]
35. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
[TBL] [Abstract][Full Text] [Related]
36. Prevention of osteoporosis with nasal salmon calcitonin: effect of anti-salmon calcitonin antibody formation.
Reginster JY; Gaspar S; Deroisy R; Zegels B; Franchimont P
Osteoporos Int; 1993 Sep; 3(5):261-4. PubMed ID: 8400608
[TBL] [Abstract][Full Text] [Related]
37. [Effectiveness of intranasal salmon calcitonin treatment in postmenopausal osteoporosis].
Kopaliani M
Georgian Med News; 2005 Apr; (121):38-42. PubMed ID: 15908722
[TBL] [Abstract][Full Text] [Related]
38. Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis.
Dursun N; Dursun E; Yalçin S
Int J Clin Pract; 2001 Oct; 55(8):505-9. PubMed ID: 11695068
[TBL] [Abstract][Full Text] [Related]
39. Salmon calcitonin and calcium in the treatment of male osteoporosis: the effect on bone mineral density.
Erlacher L; Kettenbach J; Kiener H; Graninger W; Kainberger F; Pietschmann P
Wien Klin Wochenschr; 1997 Apr; 109(8):270-4. PubMed ID: 9163888
[TBL] [Abstract][Full Text] [Related]
40. Effect of salcatonin given intranasally on early postmenopausal bone loss.
Overgaard K; Riis BJ; Christiansen C; Hansen MA
BMJ; 1989 Aug; 299(6697):477-9. PubMed ID: 2507027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
